AdaptHealth (NASDAQ:AHCO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of AdaptHealth (NASDAQ:AHCO) from a buy rating to a strong-buy rating in a report released on Saturday.

A number of other brokerages have also recently issued reports on AHCO. Weiss Ratings lowered shares of AdaptHealth from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday. Canaccord Genuity Group raised their price target on shares of AdaptHealth from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Finally, Zacks Research raised AdaptHealth from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $13.60.

AdaptHealth Stock Down 0.3%

AHCO opened at $10.61 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.08 and a quick ratio of 0.86. AdaptHealth has a one year low of $7.11 and a one year high of $11.63. The firm has a market capitalization of $1.44 billion, a P/E ratio of 19.29, a price-to-earnings-growth ratio of 1.21 and a beta of 1.71. The company has a fifty day moving average price of $9.93 and a 200-day moving average price of $9.50.

AdaptHealth (NASDAQ:AHCO) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.05). The firm had revenue of $820.31 million for the quarter, compared to the consensus estimate of $799.62 million. AdaptHealth had a return on equity of 4.85% and a net margin of 2.53%.The company’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same period last year, the firm earned $0.15 EPS. Equities research analysts expect that AdaptHealth will post 0.88 earnings per share for the current fiscal year.

Insider Transactions at AdaptHealth

In other news, Director David Solomon Williams III sold 5,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $9.43, for a total transaction of $47,150.00. Following the sale, the director directly owned 45,045 shares in the company, valued at approximately $424,774.35. This represents a 9.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.55% of the company’s stock.

Institutional Trading of AdaptHealth

Institutional investors and hedge funds have recently modified their holdings of the stock. FNY Investment Advisers LLC acquired a new stake in AdaptHealth in the third quarter worth about $35,000. AlphaQuest LLC increased its stake in AdaptHealth by 275.7% during the 2nd quarter. AlphaQuest LLC now owns 3,941 shares of the company’s stock valued at $37,000 after purchasing an additional 2,892 shares in the last quarter. Assetmark Inc. lifted its stake in shares of AdaptHealth by 87.6% during the second quarter. Assetmark Inc. now owns 5,529 shares of the company’s stock worth $52,000 after buying an additional 2,581 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of AdaptHealth by 318.0% during the second quarter. Tower Research Capital LLC TRC now owns 9,592 shares of the company’s stock worth $90,000 after buying an additional 7,297 shares during the period. Finally, Tidal Investments LLC acquired a new position in shares of AdaptHealth in the 2nd quarter valued at $96,000. Institutional investors own 82.67% of the company’s stock.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.